Tonix Pharmaceuticals Holding Corp

NASDAQ:TNXP  
0.37
0.00 (-0.77%)
7:45:08 PM EDT: $0.38 +0.01 (+1.48%)
Earnings Announcements

Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results

Published: 11/07/2022 12:25 GMT
Tonix Pharmaceuticals Holding Corp (TNXP) - Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights.
Five Potentially Pivotal Phase 2 Or 3 Studies for Cns Programs Expected to Be in Clinic by Q1 2023.
Qtrly Net Loss Available to Common Stockholders Was $0.69 per Share, Basic and Diluted,.
Tonix Pharmaceuticals - Data From Planned Interim Analyses of Tnx-102 Sl in Phase 3 Fibromyalgia Study, Phase 2 Long Covid Study Expected Q2 2023.
Cash and Cash Equivalents Totaled Approximately $140 Million at September 30, 2022.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$1.02

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$1.38

More details on our Analysts Page.